Markus Laimer
An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
Singeisen H, Renström F, Laimer M, Lehmann R, Bilz S, Brändle M. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study. Eur J Prev Cardiol 2023; 30:1473-1481.
10.10.2023An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
10.10.2023Eur J Prev Cardiol 2023; 30:1473-1481
Singeisen Hélène, Renström Frida, Laimer Markus, Lehmann Roger, Bilz Stefan, Brändle Michael
Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023).
Gastaldi G, Lucchini B, Thalmann S, Alder S, Laimer M, Brändle M, Wiesli P, Lehmann R, Working group of the SGED/SSED. Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023). Swiss Med Wkly 2023; 153:40060.
01.04.2023Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023).
01.04.2023Swiss Med Wkly 2023; 153:40060
Gastaldi Giacomo, Lucchini Barbara Stella, Thalmann Sebastien, Alder Stephanie, Laimer Markus, Brändle Michael, Wiesli Peter, Lehmann Roger, Working group of the SGED/SSED